Mark Oki Joins Achieve Life Sciences as CFO
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a leading late-stage pharmaceutical company focused on the development and commercialization of cytisinicline for nicotine dependence treatment, has exciting news. Mark Oki has taken on the vital role of Chief Financial Officer, effective immediately. With a strong financial strategy and operational skills, Mr. Oki will oversee various aspects such as financing, accounting, and investor relations, helping the company meet its objectives.
Leadership Welcome and Positive Outlook
Rick Stewart, the Chief Executive Officer of Achieve, expressed enthusiasm about Mr. Oki's extensive background in financial and operational leadership. According to Stewart, "Mark's wealth of experience is pivotal as we approach the critical stages for cytisinicline’s submission and commercialization. We're thrilled to have him on our leadership team at such a crucial moment. His expertise within public biopharma will no doubt have an immediate positive impact."
Mark Oki's Vision for Achieve
Mark Oki shared his excitement about his new role: "Achieve plays a significant part in addressing a global health crisis while enhancing financial growth and shareholder value. I see this as an incredible opportunity to contribute to the fight against nicotine dependence—a battle that affects millions of lives. My focus will be to align our financial strategies to ensure that cytisinicline reaches those who need it most."
A Proven Leader in Financial Management
With over 25 years of extensive experience in the biotechnology and pharmaceutical sectors, Mark Oki brings a wealth of knowledge. Recently, he served as CFO at Aytu BioPharma and held significant positions at Vivus LLC and Alexza Pharmaceuticals. Oki's career has been marked by his success in facilitating funding through various means, demonstrating his qualifications for steering Achieve’s financial operations.
Understanding the Stock Options Structure
To incentivize his new position, Achieve's Board of Directors has granted Mr. Oki the option to acquire 72,000 shares of the company’s common stock and 168,000 performance-based restricted stock units (RSUs). The stock options will vest over three years, with shares becoming available after fulfilling certain performance criteria.
Advancing Cytisinicline and Addressing Nicotine Dependence
Achieve Life Sciences aims to tackle the worldwide health crisis of smoking addiction through cytisinicline. It’s noteworthy that about 29 million adults smoke combustible cigarettes. Tobacco usage remains the leading cause of preventable deaths globally, accounting for more than eight million fatalities each year.
The Growing Epidemic of E-Cigarettes
Furthermore, over 11 million adults in the U.S. currently use e-cigarettes, which is a notable concern. In recent data, it was reported that around 1.6 million middle and high school students in the U.S. are engaging in vaping. The absence of FDA-approved treatments specifically targeting e-cigarette cessation puts cytisinicline in a vital position, especially as it has received the Breakthrough Therapy designation.
Cytisinicline: How It Works
Cytisinicline is a plant-based alkaloid that binds strongly to nicotinic acetylcholine receptors in the brain, making it essential for mitigating nicotine cravings. It plays a crucial role in the quest to reduce both the severity of cravings and the pleasure derived from nicotine use.
Investor Relations and Future Growth
Achieve Life Sciences is committed to advancing its mission to improve lives affected by nicotine addiction. Nicole Jones leads the investor relations team, ensuring the seamless flow of communication regarding the company's strategic initiatives and financial performance, reflecting Achieve's vision for growth and development.
Frequently Asked Questions
What role has Mark Oki been appointed to at Achieve Life Sciences?
Mark Oki has been appointed as the Chief Financial Officer of Achieve Life Sciences.
What will Mr. Oki be responsible for in his new role?
Mr. Oki will oversee the company's financial strategy, operations, accounting, investor relations, and information technology.
How does cytisinicline aim to help with nicotine addiction?
Cytisinicline works by binding to nicotinic receptors in the brain, helping to manage cravings and pleasure from nicotine use.
What is the significance of the stock options granted to Mr. Oki?
The stock options and performance-based RSUs are incentives for Mr. Oki, aligning his interests with the company's long-term success.
Why is cytisinicline considered important in the context of e-cigarettes?
With rising e-cigarette usage and no FDA-approved treatments available, cytisinicline fills a critical gap in smoking cessation aids.
